Navigation Links
MHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA
Date:12/14/2010

world for a total of 2,500 to 3,000 patients. Over 1,000 MPS IVA patients worldwide have been identified through The International Morquio Organization (IMO) survey and the BioMarin MorCAP registry program.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of its program for MPS IVA, and particularly the timing and conduct of clinical trials related thereto, and expectations regarding filings with regulatory agencies. These forward-looking statements ar
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , December 15, 2014 ... drugs for aggressive drug resistant cancers, today announces that ... a private placing from new and existing investors. ... to support the development of its pipeline of innovative ... for its lead drug candidate, BGB324, a first-in-class selective ...
(Date:12/15/2014)... Investor-Edge has initiated coverage on the ... Lilly and Company (NYSE: LLY ), Nektar Therapeutics ... ), and Novartis AG (NYSE: NVS ). Free ... http://investor-edge.com/register . On Friday, December 12, 2014, the ... Industrial Average lost 1.79%, to finish the day at 17,280.83, ...
(Date:12/15/2014)... and BOSTON , December 15, 2014 ... structure-guided drug discovery and development company, is pleased to ... the United States relating to its ... in the US significantly strengthens the global patent estate ... markets. The suite of patents recently granted ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... best policy , , ROCHESTER, ... the use of the drug therapy etanercept ineffective in treating alcoholic ... of alcohol. The results of the study are published in the ... , VIDEO ALERT: Additional audio and ...
... 9 at 11:00 am ET to Discuss Phase 2 Study ... SOUTH SAN FRANCISCO, Calif., Dec. 1 ... biopharmaceutical company focused on the development and commercialization of new ... voreloxin in acute myeloid leukemia (AML) will be presented during ...
Cached Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3
(Date:12/17/2014)... 16, 2014 (HealthDay News) -- Greater participation in music ... finds. Researchers followed kids in the nonprofit Harmony ... children in Los Angeles. Over two years, children ... in how the brain processes speech and reading, compared ... the benefits of active participation in music classes occurred ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Cancer researchers ... possible underlying genetic causes of deadly malignant pleural mesothelioma. ... research on their website. Click here to read ... University of Hawaii Cancer Center, and New York’s Langone ... malignant pleural mesothelioma patients in an effort to ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
(Date:12/15/2014)... Kenmode Precision Metal Stamping has announced that ... Quality Assurance. He brings more than 15 years ... for manufacturers in the U.S. and abroad. , ... at Sonoco Products Company in the Protective Solutions Division, ... Assurance Manager for Prince Industries, all in the Chicago ...
Breaking Medicine News(10 mins):Health News:Music Classes Boost Language Skills, Study Says 2Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
... DENVER, Oct. 11 Global Med Technologies(R),Inc. ... medical,information technology company, today reported that its ... exhibitor at the AABB,Annual Meeting and Transfusion ... ) The AABB, founded in 1947, ...
... and allows hospital pharmacies to accurately manage costs and ... ... Oct. 11 Omnicell, Inc.,(Nasdaq: OMCL ) a leading provider ... operational efficiency, today,announced the Omnicell WorkflowRx 5.0 central pharmacy automation solution.,With ...
... * concentrated Tylenol(R) Infants, Drops Plus Cold ... ... FORT WASHINGTON, Pa., Oct. 11 McNeil Consumer,Healthcare, a division of ... cough and cold products,from the market. When used as directed, these ...
... ALOKA Co., Ltd., a pioneer in the,development ... Masanobu Tada as President, and Carlos Faustmann as ... the company,s,wholly-owned European headquarters in Zug, Switzerland, with ... Global Marketing of the company as,general manager since ...
... Plan to Give Access to Affordable Health Insurance, ... Cover,All Pennsylvanians, the centerpiece of his "Prescription for Pennsylvania,",was ... held a,town meeting in Erie as part of his ... the need to lower health care costs,and expand coverage. ...
... cancer in mice - can replicate and spread in human ... the online open access journal Retrovirology, adds weight to the ... cancer. , The idea that MMTV is involved in human ... the 1990s, researchers detected MMTV in human breast tumors, but ...
Cached Medicine News:Health News:Global Med Technologies(R), Inc.'s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference 2Health News:Global Med Technologies(R), Inc.'s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference 3Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 2Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 3Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:ALOKA Appoints New Management in Europe 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 3Health News:Mouse mammary tumor virus can replicate in human cells 2
20 GA TITANIUM RETINAL FORCEPS...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Medicine Products: